Session Type: ePosters
Session Title: ePosters
Authors(s): S. Velasco De La Fuente, M. Fernández-Martinez, J. Rodríguez Lozano, D. Pablo Marcos, M. Siller, J. Calvo
Authors Affiliations(s): Microbiology Service, Hospital Universitario Marqués de Valdecilla-IDIVAL, Spain
Background:
Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicrobial activity, including methicillin-resistant Staphylococcus. Ceftobiprole is approved for the treatment of community and hospital-acquired pneumonia. Dalbavancin is a synthetic lipoglycopeptide antibiotic, it has excellent bactericidal activity against staphylococci and it’s used for treatment of acute bacterial skin infections. The large proportion of methicillin-resistant coagulase-negative staphylococci (CoNS) strains and the emergence of strains with reduced susceptibility to glycopeptides, daptomycin and/or linezolid are of concern.
The aim of this study was to investigate the in vitro activity of ceftobiprole and dalbavancin against a collection of CoNS isolates resistant to daptomycin, linezolid, vancomycin and/or teicoplanin.
Methods:A total of 228 non-duplicate CoNS isolates from clinical samples, collected between January-2012 and March-2016 were studied. All isolates were tested resistant to daptomycin, linezolid, vancomycin and/or teicoplanin using the Vitek-2 AST-626 cards (bioMérieux) and they were confirmed with Etest strips (bioMérieux). Isolates which were resistant to one or more of these antimicrobial agents were selected: Staphylococcus epidermidis (n=187), Staphylococcus hominis (n=22), Staphylococcus haemolyticus (n=16), Staphylococcus warneri (n=3) and Staphylococcus capitis (n=1). The isolates were recovered from blood (46.5%), skin and soft tissues (18.9%) abdominal specimens (10.5%), osteoarticular specimens (8.3%), cerebrospinal fluid (7.5%), urine (5.7%) and respiratory tract (2.6%).
Susceptibility testing for ceftobiprole (Basilea Pharma) and dalbavancin (Med Chem Express) were performed by EUCAST broth microdilution methodology and incubated at 35±2ºC for 16-20 hours. S. aureus ATCC 29213 was used as control strains. Results were interpreted according to 2021 EUCAST breakpoints. In case of ceftobiprole, breakpoints for S. aureus were used. MICs of dalbavancin were determined in presence of polysorbate-80.
Results:Ceftobiprole showed 96.0% susceptibility against CoNS, while dalbavancin showed 93.0% activity. Ceftobiprole and dalbavancin MIC90 were 2μg/mL and 0.125μg/mL respectively.
MICs of ceptobiprole were higher in S. hominis and S. haemolyticus (MIC90 4μg/mL). Dalbavancin exhibited higher MICs in S. haemolyticus as well as teicoplanin and daptomicin resistant CoNS (Table 1).
Conclusions:In this study ceftobiprole and dalbavancin demonstrated a potent in vitro activity against daptomycin, linezolid and glycopeptide resistant CoNS strains. Both could be a good therapeutic alternative in infections caused by these microorganisms.
Keyword(s): Ceftobiprole, Dalbavancin, StaphylococciSession Type: ePosters
Session Title: ePosters
Authors(s): S. Velasco De La Fuente, M. Fernández-Martinez, J. Rodríguez Lozano, D. Pablo Marcos, M. Siller, J. Calvo
Authors Affiliations(s): Microbiology Service, Hospital Universitario Marqués de Valdecilla-IDIVAL, Spain
Background:
Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicrobial activity, including methicillin-resistant Staphylococcus. Ceftobiprole is approved for the treatment of community and hospital-acquired pneumonia. Dalbavancin is a synthetic lipoglycopeptide antibiotic, it has excellent bactericidal activity against staphylococci and it’s used for treatment of acute bacterial skin infections. The large proportion of methicillin-resistant coagulase-negative staphylococci (CoNS) strains and the emergence of strains with reduced susceptibility to glycopeptides, daptomycin and/or linezolid are of concern.
The aim of this study was to investigate the in vitro activity of ceftobiprole and dalbavancin against a collection of CoNS isolates resistant to daptomycin, linezolid, vancomycin and/or teicoplanin.
Methods:A total of 228 non-duplicate CoNS isolates from clinical samples, collected between January-2012 and March-2016 were studied. All isolates were tested resistant to daptomycin, linezolid, vancomycin and/or teicoplanin using the Vitek-2 AST-626 cards (bioMérieux) and they were confirmed with Etest strips (bioMérieux). Isolates which were resistant to one or more of these antimicrobial agents were selected: Staphylococcus epidermidis (n=187), Staphylococcus hominis (n=22), Staphylococcus haemolyticus (n=16), Staphylococcus warneri (n=3) and Staphylococcus capitis (n=1). The isolates were recovered from blood (46.5%), skin and soft tissues (18.9%) abdominal specimens (10.5%), osteoarticular specimens (8.3%), cerebrospinal fluid (7.5%), urine (5.7%) and respiratory tract (2.6%).
Susceptibility testing for ceftobiprole (Basilea Pharma) and dalbavancin (Med Chem Express) were performed by EUCAST broth microdilution methodology and incubated at 35±2ºC for 16-20 hours. S. aureus ATCC 29213 was used as control strains. Results were interpreted according to 2021 EUCAST breakpoints. In case of ceftobiprole, breakpoints for S. aureus were used. MICs of dalbavancin were determined in presence of polysorbate-80.
Results:Ceftobiprole showed 96.0% susceptibility against CoNS, while dalbavancin showed 93.0% activity. Ceftobiprole and dalbavancin MIC90 were 2μg/mL and 0.125μg/mL respectively.
MICs of ceptobiprole were higher in S. hominis and S. haemolyticus (MIC90 4μg/mL). Dalbavancin exhibited higher MICs in S. haemolyticus as well as teicoplanin and daptomicin resistant CoNS (Table 1).
Conclusions:In this study ceftobiprole and dalbavancin demonstrated a potent in vitro activity against daptomycin, linezolid and glycopeptide resistant CoNS strains. Both could be a good therapeutic alternative in infections caused by these microorganisms.
Keyword(s): Ceftobiprole, Dalbavancin, Staphylococci
Microbiology Service, Hospital Universitario Marqués de Valdecilla. Santander, Spain
Session Type: ePosters
Session Title: ePosters
Authors(s): S. Velasco De La Fuente, M. Fernández-Martinez, J. Rodríguez Lozano, D. Pablo Marcos, M. Siller, J. Calvo
Authors Affiliations(s): Microbiology Service, Hospital Universitario Marqués de Valdecilla-IDIVAL, Spain
Background:
Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicrobial activity, including methicillin-resistant Staphylococcus. Ceftobiprole is approved for the treatment of community and hospital-acquired pneumonia. Dalbavancin is a synthetic lipoglycopeptide antibiotic, it has excellent bactericidal activity against staphylococci and it’s used for treatment of acute bacterial skin infections. The large proportion of methicillin-resistant coagulase-negative staphylococci (CoNS) strains and the emergence of strains with reduced susceptibility to glycopeptides, daptomycin and/or linezolid are of concern.
The aim of this study was to investigate the in vitro activity of ceftobiprole and dalbavancin against a collection of CoNS isolates resistant to daptomycin, linezolid, vancomycin and/or teicoplanin.
Methods:A total of 228 non-duplicate CoNS isolates from clinical samples, collected between January-2012 and March-2016 were studied. All isolates were tested resistant to daptomycin, linezolid, vancomycin and/or teicoplanin using the Vitek-2 AST-626 cards (bioMérieux) and they were confirmed with Etest strips (bioMérieux). Isolates which were resistant to one or more of these antimicrobial agents were selected: Staphylococcus epidermidis (n=187), Staphylococcus hominis (n=22), Staphylococcus haemolyticus (n=16), Staphylococcus warneri (n=3) and Staphylococcus capitis (n=1). The isolates were recovered from blood (46.5%), skin and soft tissues (18.9%) abdominal specimens (10.5%), osteoarticular specimens (8.3%), cerebrospinal fluid (7.5%), urine (5.7%) and respiratory tract (2.6%).
Susceptibility testing for ceftobiprole (Basilea Pharma) and dalbavancin (Med Chem Express) were performed by EUCAST broth microdilution methodology and incubated at 35±2ºC for 16-20 hours. S. aureus ATCC 29213 was used as control strains. Results were interpreted according to 2021 EUCAST breakpoints. In case of ceftobiprole, breakpoints for S. aureus were used. MICs of dalbavancin were determined in presence of polysorbate-80.
Results:Ceftobiprole showed 96.0% susceptibility against CoNS, while dalbavancin showed 93.0% activity. Ceftobiprole and dalbavancin MIC90 were 2μg/mL and 0.125μg/mL respectively.
MICs of ceptobiprole were higher in S. hominis and S. haemolyticus (MIC90 4μg/mL). Dalbavancin exhibited higher MICs in S. haemolyticus as well as teicoplanin and daptomicin resistant CoNS (Table 1).
Conclusions:In this study ceftobiprole and dalbavancin demonstrated a potent in vitro activity against daptomycin, linezolid and glycopeptide resistant CoNS strains. Both could be a good therapeutic alternative in infections caused by these microorganisms.
Keyword(s): Ceftobiprole, Dalbavancin, StaphylococciSession Type: ePosters
Session Title: ePosters
Authors(s): S. Velasco De La Fuente, M. Fernández-Martinez, J. Rodríguez Lozano, D. Pablo Marcos, M. Siller, J. Calvo
Authors Affiliations(s): Microbiology Service, Hospital Universitario Marqués de Valdecilla-IDIVAL, Spain
Background:
Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicrobial activity, including methicillin-resistant Staphylococcus. Ceftobiprole is approved for the treatment of community and hospital-acquired pneumonia. Dalbavancin is a synthetic lipoglycopeptide antibiotic, it has excellent bactericidal activity against staphylococci and it’s used for treatment of acute bacterial skin infections. The large proportion of methicillin-resistant coagulase-negative staphylococci (CoNS) strains and the emergence of strains with reduced susceptibility to glycopeptides, daptomycin and/or linezolid are of concern.
The aim of this study was to investigate the in vitro activity of ceftobiprole and dalbavancin against a collection of CoNS isolates resistant to daptomycin, linezolid, vancomycin and/or teicoplanin.
Methods:A total of 228 non-duplicate CoNS isolates from clinical samples, collected between January-2012 and March-2016 were studied. All isolates were tested resistant to daptomycin, linezolid, vancomycin and/or teicoplanin using the Vitek-2 AST-626 cards (bioMérieux) and they were confirmed with Etest strips (bioMérieux). Isolates which were resistant to one or more of these antimicrobial agents were selected: Staphylococcus epidermidis (n=187), Staphylococcus hominis (n=22), Staphylococcus haemolyticus (n=16), Staphylococcus warneri (n=3) and Staphylococcus capitis (n=1). The isolates were recovered from blood (46.5%), skin and soft tissues (18.9%) abdominal specimens (10.5%), osteoarticular specimens (8.3%), cerebrospinal fluid (7.5%), urine (5.7%) and respiratory tract (2.6%).
Susceptibility testing for ceftobiprole (Basilea Pharma) and dalbavancin (Med Chem Express) were performed by EUCAST broth microdilution methodology and incubated at 35±2ºC for 16-20 hours. S. aureus ATCC 29213 was used as control strains. Results were interpreted according to 2021 EUCAST breakpoints. In case of ceftobiprole, breakpoints for S. aureus were used. MICs of dalbavancin were determined in presence of polysorbate-80.
Results:Ceftobiprole showed 96.0% susceptibility against CoNS, while dalbavancin showed 93.0% activity. Ceftobiprole and dalbavancin MIC90 were 2μg/mL and 0.125μg/mL respectively.
MICs of ceptobiprole were higher in S. hominis and S. haemolyticus (MIC90 4μg/mL). Dalbavancin exhibited higher MICs in S. haemolyticus as well as teicoplanin and daptomicin resistant CoNS (Table 1).
Conclusions:In this study ceftobiprole and dalbavancin demonstrated a potent in vitro activity against daptomycin, linezolid and glycopeptide resistant CoNS strains. Both could be a good therapeutic alternative in infections caused by these microorganisms.
Keyword(s): Ceftobiprole, Dalbavancin, Staphylococci